DGAP-News APONTIS PHARMA AG sets placement price for its IPO at EUR 19.00 per share
DGAP-News: APONTIS PHARMA AG / Key word(s): IPO
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE
WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THE PRESS RELEASE.
- Total placement volume of EUR 101 million including over-allotment and upsize options
- Market capitalization post-money to total EUR 162 million based on placement price
- Post-IPO free float expected to amount to 62% assuming greenshoe option exercised in full
- First day of trading at Frankfurt Stock Exchange (Scale) scheduled for 11 May 2021 under ticker symbol APPH
Monheim am Rhein, 06 May 2021. APONTIS PHARMA AG ("APONTIS PHARMA" or "Company") a leading pharmaceutical company specializing in Single Pills in the German market, has set the placement price for its initial public offering ("IPO") at EUR 19.00 per share.
In total, 5,290,000 ordinary bearer shares with no par value were placed with investors in the IPO. The placement comprises 2,000,000 new shares from a capital increase against cash contributions, 1,600,000 secondary shares in a base deal and 1,000,000 secondary shares from the exercise of an upsize option by the major shareholder Paragon Partners as well as 690,000 secondary shares provided by Paragon Partners in connection with an over-allotment option, corresponding to a total placement volume of EUR 101 million.
Based on the placement price, APONTIS PHARMA's market capitalization amounts to EUR 162 million post-money. Upon completion of the IPO and assuming full exercise of the greenshoe option, the expected free float will amount to 62%, which will allow for liquid trading of the Company's shares.
The existing shareholders Paragon Partners and APONTIS PHARMA'S Management will continue to hold 31% and 7%, respectively, of the Company's shares following the placement.
|Diskussion: APONTIS Pharma - Patientenversorger aus Nordrhein-Westfalen|